Diane E. Durecki

599 total citations
8 papers, 374 citations indexed

About

Diane E. Durecki is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Diane E. Durecki has authored 8 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Genetics. Recurrent topics in Diane E. Durecki's work include PARP inhibition in cancer therapy (4 papers), Multiple Myeloma Research and Treatments (3 papers) and DNA Repair Mechanisms (2 papers). Diane E. Durecki is often cited by papers focused on PARP inhibition in cancer therapy (4 papers), Multiple Myeloma Research and Treatments (3 papers) and DNA Repair Mechanisms (2 papers). Diane E. Durecki collaborates with scholars based in United States and Poland. Diane E. Durecki's co-authors include M. Mietzel, Keith Stockerl‐Goldstein, Tara Anderson, Kent A. Griffith, Ravi Vij, Sundar Jagannath, Daniel R. Couriel, Andrzej Jakubowiak, Kristen Detweiler‐Short and Dominik Dytfeld and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Diane E. Durecki

8 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diane E. Durecki United States	6	320	320	170	42	16	8	374
Antonio Palumbo Netherlands	3	355 1.1×	430 1.3×	252 1.5×	39 0.9×	15 0.9×	5	451
Edvan de Queiroz Crusoé Brazil	8	233 0.7×	229 0.7×	156 0.9×	33 0.8×	21 1.3×	41	353
Sara Bringhen Italy	3	310 1.0×	376 1.2×	224 1.3×	35 0.8×	15 0.9×	4	397
Evžen Gregora Czechia	11	218 0.7×	253 0.8×	130 0.8×	43 1.0×	22 1.4×	29	301
A. Keith Stewart United States	5	184 0.6×	221 0.7×	118 0.7×	37 0.9×	21 1.3×	13	257
Michael S. Ondovik United States	8	311 1.0×	261 0.8×	145 0.9×	74 1.8×	12 0.8×	12	392
Kathryn McDonnell United States	7	373 1.2×	397 1.2×	193 1.1×	32 0.8×	15 0.9×	11	418
Dixil Francis United States	4	197 0.6×	231 0.7×	100 0.6×	32 0.8×	18 1.1×	5	279
Clotilde Cangialosi Italy	8	365 1.1×	433 1.4×	259 1.5×	30 0.7×	17 1.1×	16	460
Pamela Hardwick United States	6	227 0.7×	286 0.9×	183 1.1×	34 0.8×	12 0.8×	13	305

Countries citing papers authored by Diane E. Durecki

Since Specialization

Citations

This map shows the geographic impact of Diane E. Durecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diane E. Durecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diane E. Durecki more than expected).

Fields of papers citing papers by Diane E. Durecki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diane E. Durecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diane E. Durecki. The network helps show where Diane E. Durecki may publish in the future.

Co-authorship network of co-authors of Diane E. Durecki

This figure shows the co-authorship network connecting the top 25 collaborators of Diane E. Durecki. A scholar is included among the top collaborators of Diane E. Durecki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diane E. Durecki. Diane E. Durecki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Amengual, Jennifer E., Aung M. Tun, Victor Yazbeck, et al.. (2024). Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma. Blood. 144(Supplement 1). 3112–3112. 2 indexed citations

Cecchini, Michael, Zenta Walther, Wei Wei, et al.. (2023). NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer Research Communications. 3(6). 1113–1117. 2 indexed citations

Pilat, Mary Jo, Derek Shyr, Yu Shyr, et al.. (2023). Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer Research Communications. 3(2). 192–201. 18 indexed citations

Shah, Ritu, Scott A. Boerner, Jing Li, et al.. (2022). Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.. Journal of Clinical Oncology. 40(16_suppl). 2035–2035. 5 indexed citations

LoRusso, Patricia, Sara M. Tolaney, Shukmei Wong, et al.. (2015). Abstract CT325: Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response. Cancer Research. 75(15_Supplement). CT325–CT325. 5 indexed citations

Jakubowiak, Andrzej, Dominik Dytfeld, Kent A. Griffith, et al.. (2013). Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.. Journal of Clinical Oncology. 31(15_suppl). 8543–8543. 13 indexed citations

Jakubowiak, Andrzej, Dominik Dytfeld, Kent A. Griffith, et al.. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 120(9). 1801–1809. 311 indexed citations

Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2011). Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood. 118(21). 631–631. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact